Updates on the Potential Role of ctDNA in Managing Breast Cancer Patients Across the Disease Continuum

Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.

EP. 1: An Overview of Minimal Residual Disease (MRD) Testing

January 25th 2022

Expert oncologist Aditya Bardia, MD, MPH, provides a broad overview of minimal residual disease testing across a number of tumor types and clinical settings.

EP. 2: Applications of ctDNA Assessment in Early Breast Cancer

January 25th 2022

Barry Rosen, MD, provides an overview of circulating tumor DNA’s role in early stage breast cancer detection and management.

EP. 3: Applications of ctDNA Assessment in Metastatic Breast Cancer and Relapse

February 1st 2022

Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.

EP. 4: Role of ctDNA in the Neoadjuvant Setting of Breast Cancer

February 1st 2022

Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.

EP. 5: Role of ctDNA in the Adjuvant Setting of Breast Cancer

February 9th 2022

Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.

EP. 6: ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection

February 9th 2022

A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.

EP. 7: Other Clinical Studies on ctDNA Use in Breast Cancer

February 16th 2022

Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.

EP. 8: Practical Advice on the Use of ctDNA Testing in Breast Cancer

February 16th 2022

Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.